SPY313.04-0.74 -0.24%
DIA258.50-0.54 -0.21%
IXIC10,362.15+18.26 0.18%

UBS Downgrades Intercept Pharmaceuticals to Neutral, Lowers Price Target to $57

UBS analyst Navin Jacob downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Buy to Neutral and lowers the price target from $135 to $57.

Benzinga · -
UBS analyst Navin Jacob downgrades Intercept Pharmaceuticals (NASDAQ: ICPT) from Buy to Neutral and lowers the price target from $135 to $57.